Companies in #Systemic Lupus Erythematosus
Found 3 companies operating in this sector.
Adicet Bio is a clinical-stage biotechnology company based in Redwood City, California, discovering and developing off-the-shelf allogeneic gamma delta T cell therapies engineered with chimeric antigen receptors for autoimmune diseases and cancer, alongside a preclinical in vivo CAR-T platform. Its lead candidate, prula-cel (formerly ADI-001), is an anti-CD20 CAR gamma delta T cell therapy being developed in systemic lupus erythematosus with or without lupus nephritis; on September 28, 2026 the company reported updated Phase 1 data from 22 efficacy-evaluable patients showing 54% DORIS remission at 12 months and complete renal response in 50% of evaluable lupus nephritis patients after a single dose off immunosuppression, with no cases of IEC-HS and no ICANS, and said it expects to begin a pivotal study in the fourth quarter of 2026. Its second program, ADI-212, is an anti-CD70 CAR gamma delta T cell therapy with an FDA-cleared IND in metastatic castration-resistant prostate cancer and a Phase 1 study expected to initiate in the fourth quarter of 2026.
Cullinan Therapeutics is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company developing targeted therapies for autoimmune diseases and cancer. Its clinical-stage portfolio includes CLN-978, a wholly owned CD19xCD3 bispecific T cell engager being studied as an off-the-shelf subcutaneous therapy for rheumatoid arthritis, systemic lupus erythematosus and Sjögren's disease, and zipalertinib, a brain-penetrant EGFR exon 20 insertion inhibitor developed in partnership with Taiho Oncology for non-small cell lung cancer that reported positive Phase 3 REZILIENT3 results in September 2026. The company was founded in 2016, listed on Nasdaq in January 2021, and is led by President and Chief Executive Officer Nadim Ahmed.
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors. Its lead candidate, EB103, is in a Phase I/II clinical trial for diffuse large B-cell lymphoma, and the company is advancing EB104 preclinically for diffuse large B-cell lymphoma and acute lymphocytic leukemia and EB201 preclinically for systemic lupus erythematosus. The company's ARTEMIS cell receptor platform is designed to develop and commercialize T-cell therapies targeting CD19 and CD22 for hematologic malignancies, and it has a collaboration with Eureka Therapeutics and Imugene covering solid-tumor treatments that combine Imugene's CF33-CD19t with EB103. Estrella Immunopharma is a subsidiary of Eureka Therapeutics and is headquartered in Emeryville, California. The company trades on the Nasdaq Capital Market, where it disclosed on September 1, 2026 that it had received a notification of non-compliance with continued listing standards, and it has until March 1, 2027 to restore its market value of listed securities above $35 million for at least ten consecutive days.